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The Accreditation Council for Graduate Medical Education(ACGME) recently issued the final draft of its Residency
Duty Hours Program Requirements for final community
comment. These requirements, their nature and their specificity,
have met with a wide range of responses. I thought it might be
instructive for you, our alumni, to understand the issues, and to
understand our philosophy and approach to these difficult
educational and clinical issues.
To begin with, I must declare two potential influences,
or in the current parlance, conflicts inherent in my
approach. The first is that I am an Internal Medicine
educator and former residency program director. As
such, I have spent much of my career leading
residency programs in Internal Medicine under similar
duty hours limitations. The second is that I am
currently the Chair of the Residency Review
Committee for Internal Medicine, and responsible for
the writing and implementation of program require-
ments for the 390 Internal Medicine Residency
Programs, and over 1,400 fellowship programs in the subspe-
cialties of Internal Medicine.
Over the past 18 years, seminal events have shaped the course of
the debate over the regulation of resident duty hours, and
residents’ supervision by faculty. The first was the report of the
Bell Commission in New York State, with subsequent regulation
of the work environment and duty hours for all residents within
that state. New York has within its borders approximately 20% of
the residents and residency programs of the United States. Thus,
while the regulations applied only to New York State, the impact
was felt nationally. Internal Medicine, Anesthesiology,
Emergency Medicine, and Pediatrics enacted, in various forms,
specific limitations on resident hours and responsibilities.
However, most specialties did not enact formal, quantitative
regulation of duty hours for residents. The second event was the
Institute of Medicine Report that called attention to the issue of
medical errors and patient safety. This report has been utilized
heavily to justify limitations in duty hours and responsibilities as
a tool to decrease medical errors. The recent (failed) OSHA
petition, and the pending federal legislation concerning govern-
mental oversight and control of resident duty hours have
provided tremendous impetus for self-regulation by the
profession. As the science of sleep has evolved, concerns
regarding hours of consecutive “time on task” and acute and
chronic sleep deprivation and its impact on the physician in
training have been expressed by many. Finally, there are many
who believe: that residents are working too many hours
(especially early in their training); that educational programs are
configured largely around the patient care needs of the
institution and its faculty rather than the educational needs of the
residents; and that the cumulative impact of chronic sleep
deprivation and related stress both compromises education, and
may adversely influence the development of empathy,
compassion, and altruism in the young clinician. There are
equally committed educators who believe that residents only
learn to cope with the rigors of clinical practice by being “trained
and tested” under the circumstances of duty hours in excess of
these limits. Hence the debate within the profession, not only
about the need for regulation of duty hours, but also the nature
of that regulation, the specificity of regulation, and the time
course for implementation of any regulation.
The influence of potential Congressional intrusion into
regulation of the educational environment of
physicians, as well as an overwhelming desire to
constructively deal with the heterogeneity (by
specialty) of the approach to these issues, has
resulted in the ACGME proposing uniform minimum
standards regarding duty hours.
The duty hour requirements center around 4 major
limits on resident work:
1. Residents must not work more than 80 hours per
week, when averaged over 4 consecutive weeks.
(Currently residents might work 100 hours per week, or more.)
2. Residents must have one day completely free from program
related responsibilities each week, when averaged over 4 consec-
utive weeks. (In many programs, residents receive only 0-2 days
off per month.)
3. Residents must not work more than 24 consecutive hours in
direct acute patient care responsibilities. Residents are permitted
an additional 6 hours in the hospital or program, to attend to
continuity of care for their patients, to attend continuity clinics,
or to attend educational events in the program. (The current
paradigm is 36- to 40-hour on call shifts during which they may,
or may not, get any sleep or rest.)
4. Residents must have a minimum of 10 hours of duty free time
between assignments. (New York state regulations require 8
hours between episodes of responsibility.)
In addition, there are requirements regarding the monitoring of
resident stress, sleep deprivation, and moonlighting.
Akey issue in understanding the impact of these requirementsrelates to the Balanced Budget Act of 1998, in which institu-
tional resident complements were capped (through capping of
GME reimbursement). Limits on expansion of the resident
complement narrow the options of program directors in
satisfaction of these requirements. Further, all teaching hospitals
are in the midst of absorbing reduction of the Medicare Indirect
Graduate Medical Education payments, which will have signif-
icant adverse impact on the finances of all these institutions.
These requirements, in the context of existing residency
programs and resident complements, as well as the realities of the
current financial status of most teaching institutions, will be very
difficult to implement. In smaller programs, residents will work
fewer hours, but the institutional patient load will not change.
Resources for others to care for portions of the patient
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population will be scarce. There are only two “linear” institu-
tional responses to this event. Either the remaining available
residents (a larger proportion of the residents will be off duty at
any given time) or the attending physician of record will care for
the patient. The institution might design and implement nonedu-
cational system adaptations that answer the clinical needs while
protecting the integrity of the educational program. This could
include “night medicine” rotations, short and long call rotations,
or the hiring of non-physician extenders to provide the services
previously provided by residents.
I believe that these adaptations are merely diversions from a more
fundamental, more complex question that must now be asked.
That is, do we need to closely examine, and fundamentally alter,
the current inpatient clinical care/medical education paradigm of
most major teaching hospitals and academic medical centers? Is
the current model of care, and the educational program built
around the delivery of clinical service, so compromised by the
pressures on resource utilization, length of stay, and enhanced
volume requirements that the addition of duty hours limitations
brings the system to its knees? Or, as Jim Bagian '77 (Director of
the Veterans Affairs National Center for Patient Safety) might
say, does this give us the opportunity to challenge and change
the systems of care rendered in our academic medical centers?
Can we use this opportunity to actually enhance both patient
care, as well as education?
The traditional practice model of a single doctor caring for a
single patient, day or night, year in and year out, has largely been
supplanted by groups of physicians caring for a patient. While it
is usually true that a single patient identifies a single physician in
such a group as “their doctor,” the doctor’s colleagues participate
in the care of the patient. We persist, however, in defining
“continuity of care” as the continuous availability of a clinician to
a given patient, and continuous hours of contact time essential in
the education of the physician.
To a great extent, I agree with the concept that physicians intraining need to be involved with the care of particular
patients over a significant period of their hospital stay, as well as
observe patients over time in the ambulatory setting. One key
question to ask, however, is what is so magical about 36 hours of
continuous care, and how is that concept applicable to the
patient who is admitted in the 35th hour? Patients are admitted
to residents along the time course of their duty responsibilities,
not just at the start of their “on call” day. As one begins to look at
the true nature of “continuity” as we currently operationalize it
in educational programs, the paradigm of continuous observation
and involvement begins to crumble. Indeed, it actually ended
when interns were no longer imprisoned in the hospital, or
residents no longer resided in the hospital (1950s). Whether the
medicine resident who performs the history and physical and
orders the diagnostic evaluation and therapeutic intervention, or
the surgical resident who assists the attending physician in the
surgical procedure, they need to observe the course of their
patient, and learn how to intervene to achieve the desired
outcomes. The also, however, need to learn how to work with other
physicians to achieve the desired outcomes for their patients, as that
is the practice environment they will encounter upon graduation.
What about continuity for the individual patient? Leaving aside the
issues related to fatigue in the terminal hours of a 36-40 hour shift,
what happens in most traditional call rotations to the patient? Their
care is usually supervised each night by a physician who has not
participated in their care. On an every fourth night rotation, the
patient sees four (4) different residents. Is that continuity of care for
that individual patient? There are seven unique transitions in
information over four days, three of which (transfer of information
to physicians who have had no previous contact with the patient)
we know are opportunities for error introduction. In the fast paced,
complicated world of inpatient care, is this the best system of
clinical care and education we can design?
These are but a few of the issues that each residency program, and
each sponsoring institution will struggle with over the next six
months, anticipating the implementation of these regulations in
July, 2003. One concept must be held sacrosanct as we struggle to
redefine the clinical educational paradigm. The sense of duty and
responsibility to patients must be emphasized and reinforced in
each and every educational program. We must redefine how we
express altruism for each individual patient. We must emphasize
how we define commitment, excellence in patient care, and profes-
sionalism. We must hold both trainees and faculty to the highest
standards in these dimensions.
Finally, many have questioned the commitment of students andresidents in this “next generation” to medicine, and their
patients. I have been around long enough to have heard that
discussion about my generation, as well as the generations of the
'80s and '90s. I can imagine that the commitment of young
physicians in the 1950s was challenged when they no longer lived in
the hospital as interns. Whenever change or challenges to long held
beliefs occur, it is natural to ask these questions. I can, from my
vantage point here at Jefferson, answer categorically that the
commitment to professionalism, and to the care of each individual
patient is strong and unwavering in our students and residents. This
is a tribute to them, their families (who have instilled in them the
values of professionalism), and their mentors and faculty.
We must seize the opportunity raised by these requirements to
enhance the systems of care and education in our teaching hospitals,
and further strengthen the trust of our patients in our system of
learning in the context of serving those entrusted to our care. Our
common goal is the provision of excellent, patient centered care to
each person entrusted to us, as well as the education of outstanding
compassionate physicians to serve our nation. 
At Jefferson, we are rising to this challenge.
Please accept from all the faculty, staff, students, residents and
administration here at Jefferson our warmest wishes for a happy and
healthy holiday season!
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As reported in the June Bulletin, Arthur M. Feldman MD, PhDbecame the Magee Professor and Chairman of the Department of
Medicine in July. Since taking on this post, Dr. Feldman has had the
opportunity to explore how medicine at Jefferson functions and has
begun to formulate wide-ranging plans for the future. His primary
goals are to create new and exciting clinical programs to complement
ongoing activities in the Department of Medicine and to enhance
both clinical and basic research. In addition, Dr. Feldman has
devoted much of his early time at Jefferson on the development of the
CARE Project, a performance
improvement initiative that
will introduce the concepts of
practice guidelines, process
indicators, and outcome-
driven medicine to students,
residents, and faculty. “The
Department of Medicine at
Jefferson has a rich tradition of
excellence in clinical care
going back 175 years,” he
stated. “Our goals for the
future are to try and build on
that platform of excellence.”
Through new programs and
practices, Dr. Feldman hopes
to create new opportunities to
treat patients. For example, in
collaboration with the
Department of Surgery, he
hopes to attract a group of
experts in heart failure and
cardiac transplantation. These
programs have not previously
been available within the Jefferson community. Furthermore, in
collaboration with strong clinical programs in Surgery, Radiation
Oncology, Bone Marrow Transplantation, Melanoma, and
Hematologic Diseases, Dr. Feldman hopes to create centers of
excellence for the treatment of patients with solid tumors.
The growth of basic research will focus around the development of
the new Center for Translational Medicine. “So often, we build
medicine research programs in silos. One program doesn’t talk to the
other. There are duplication of interests, and resources are wasted,”
he stated.
However, by recruiting outstanding scientists around a group of key
core facilities, Dr. Feldman believes that Jefferson can develop an
interdisciplinary collaborative group that can push forward exciting
frontiers of scientific investigation. “Indeed, there are good role
models within our own environment for this type of research
structure, including the Farber Institute for the Neurosciences and
the Kimmel Cancer Center,” noted Feldman.
In an effort to increase Jefferson’s clinical research capabilities, Dr.
Feldman wants to establish an infrastructure within the Department
of Medicine that will facilitate clinical trials. “Often when an
individual investigator wants to do clinical research, there isn’t an
infrastructure to support him,” he said. “There is no one to do the
budgeting and negotiations with the company…no one to help plow
through the large number of Federal regulations…and no facility for
training research nurses and fellows.”
By providing an infrastructure within the Department of Medicine,
Dr. Feldman believes that “we can provide services and support so
that the steps between a company approaching a Jefferson investi-
gator or an investigator developing a novel idea and the actual
enrollment of patients becomes a relatively seamless and expeditious
event.”
From a training perspective, he said “We need to take better
advantage of outstanding resources within our community, including
the training program in the Division of Clinical Pharmacology and
the new MPH program in the University. The days are over when a
physician could simply participate in a clinical trial without didactic
training, a qualified staff, and administrative support.”
Dr. Feldman also hopes to improve patient outcomes, increase
efficiency, decrease resource utilization, and enhance inpatient bed
access and capacity by achieving “best practice” indicators consistent
with national treatment guidelines and reducing variations in care.
“While improving care, these efforts will also allow us to introduce
the concepts of practice guidelines, process indicators, and outcome-
driven medicine to our students, residents, and fellows, thereby
improving their educational experience and better preparing them for
practice in the 'real world,' ” Feldman stated.
Under the leadership of Howard Weitz ’78 and Geno Merli ’75, the
CARE Project will initially focus on four disease states: heart failure,
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acute coronary syndromes, atrial fibrillation, and community
acquired pneumonia. Divided into four focus groups, a multidisci-
plinary team consisting of full-time faculty, voluntary faculty, house
staff, nursing staff, and hospital administrators will initiate programs
in the pre-hospital setting, the in-hospital setting, and the post-
discharge period that will insure optimization of care.
For example, a Rapid Triage Unit for heart failure patients and a
Chest Pain Center for rapid treatment of patients with acute coronary
syndromes will be a key aspect of improving care for patients with
these disease states. Furthermore, standardized admission orders,
standardized discharge orders, and a post-discharge disease
management strategy will be expected to facilitate improved guideline
compliance, decreased length of stay, diminish 30-day readmission
rates, and improved patient outcomes and satisfaction. “Through
collaborative interactions with the Office of Health Policy and
Clinical Outcomes of TJU, the University Health Consortium, and the
Case Management Office of the TJU Hospital, we will be able to
quantify our accomplishments,” he said.
Dr. Feldman is extremely enthusiastic and optimistic about the future
of the Department of Medicine at Jefferson. “This is a unique
institution,” he stated. “We have strong and experienced leadership
in the Medical College, the University, and the Hospital; a highly
talented and dedicated faculty and staff; a committed patient base;
outstanding house staff; a prime location in Center City; and a long
and rich history of clinical excellence.”
“However,” he continued, “We also live in a medical environment
that has disadvantaged the academic medical center. Thus, we must
be entrepreneurial, innovative, collaborative and aggressive as we face
the challenges of the future, and it will be important for all of us to
work together with one clear goal: to provide the best care possible
for our patients.”
Dr. Feldman's Research Program 
at Jefferson
Heart failure is a disease of epidemic proportions in the U.S. affecting
more than five million people of all ages. There will be approximately
400,000 new cases recognized this year, and people with newly
diagnosed heart failure have a five-year prognosis that is worse than
virtually all cancers. As our society ages, it is expected that the
number of patients with heart failure will increase over two-fold by
2016.
Arthur Feldman MD, PhD, the incoming Magee Professor and Chair
of Medicine, has focused his research interests on heart failure for the
past 20 years. “Heart failure is the number one DRG for Jefferson
University Hospital,” he stated. “It’s the number one discharge
diagnosis for people over the age of 65. It will account for a million
hospitalizations this year, and costs the health care economy over 60
billion dollars.”
Heart failure is a condition in which the heart loses its ability to
pump enough blood through the body. This loss of pumping action is
usually attributable to weakening of the heart muscle, but can also be
attributed to thickening of the heart muscle. The former is referred to
as a dilated cardiomyopathy, while the latter is referred to as
hypertrophic cardiomyopathy. In patients with dilated cardiomy-
opathy, the most common cause of heart muscle dysfunction is heart
damage, such as occurs during a heart attack or, less commonly,
during a viral infection of the heart. 
According to Dr. Feldman, one cause of the increased incidence of
heart failure is that people are living longer after experiencing a heart
attack. This improved survival is due to new technologies, such as
stents and thrombolytic therapy (clot busters) that effectively
improve survival in patients who have a heart attack. “If you look at
people in their 70s and 80s, it’s been suggested that as many as two in
10 will have or will develop heart failure. So, as the population ages
and the Baby Boomers move into their later years, the incidence of
the disease increases,” he explained.
When Dr. Feldman began his research into heart failure some two
decades ago, physicians had relatively few treatment options of offer
their patients. “Very little was known about the basic pathology
responsible for the development of heart failure or how best to treat
the condition,” he stated. “Therefore, we focused our work on trying
to understand the causes of the disease at the protein and molecular
level with our goal being to translate those findings into the clinical
arena.”
Dr. Feldman explained that his foray into the genetics of heart failure
began about 15 years ago with two fundamental observations, which
led him and his colleagues to hypothesize that fundamental differ-
ences in the genetic make-up of patients resulted in marked
disparities in response to pharmacologic therapy. “First,” he said, “we
had an interesting young man who presented with all of the signs and
symptoms of heart failure: fatigue shortness of breath, and marked
fluid accumulation or edema in his lower extremities and abdomen.
By echocardiography, his heart was markedly dilated with diminished
function.”
“It turned out that this young patient had severe hypothyroidism,” he
continued. “When his thyroid function was treated, his heart
returned to virtually normal size and function. A return to normal
function was highly unusual as heart failure was generally viewed as
an irreversible disease. Second, we found that some patients
responded quite well to medical therapy while others had no
response whatsoever.”
Dr. Feldman and his colleagues obtained biopsies of the heard muscle
from the young man with hypothyroidism and heart failure.
Molecular analysis of the biopsies, using techniques developed in Dr.
Feldman’s laboratory, revealed that the return of normal function in
this patient was accompanied by normalization of the expression of a
group of proteins that were critically important to normal heart
function. Interestingly, studies by other laboratories had
demonstrated that the genes whose proteins were normalized after
thyroid hormone treatment were sensitive to a peptide called “tumor
necrosis factor alpha” or TNF-alpha. While this protein was known
to be important in the development of inflammation, it was not
thought to be produced by the heart. To test its importance in the
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heart, Dr. Feldman and his colleagues created transgenic mice that
were bred to over-express TNF-alpha selectively in the heart. “It
turns out that if you over-express TNF-alpha in mice, they will
develop a form of heart failure that recapitulates what you seen in
humans: the heart dilates, the walls become thin, the contraction of
the heart is weakened, the extra-cellular matrix becomes very thick
and brittle,” he explained. 
When mice over-expressing TNF-alpha were treated with anti-TNF
therapy, the development of heart failure was completely blocked.
Unfortunately, when anti-TNF strategies were evaluated in patients
with heart failure, they did not show the same benefits seen in the
studies in the laboratory. However, this disappointment might have
led to improved understanding of both heart muscle disease, as well
as the role of genetics in treating patients with heart failure.
In pursuing the effects of TNF-alpha expression in the heart, Dr.
Feldman and his colleagues made two interesting discoveries. The
first was that there were vast differences between different strains of
mice. The second was that male mice had a much poorer prognosis
than female mice. Feldman explained that in some strains of mice,
heart failure was extremely well tolerated, while other strains of mice
barely lived past six weeks of age. In addition, male mice had a much
shorter survival than female mice, regardless of the strain of mice.
“While these strain and gender differences were interesting, they led
us to suspect that genetic differences might account for the marked
differences in survival we had seen amongst different patients having
the same degree of heart muscle damage,” he said.
Indeed, when Dr. Feldman and his colleagues looked at a large group
of patients with heart failure, they found that those patients having a
mutation in a gene that encoded for the production of a protein called
“angiotensin converting enzyme” had a far worse prognosis than did
patients who did not harbor the mutation. However, the patients who
had the mutation were far more likely to respond to medical therapy.
“Thus,” he stated, “genetic differences in populations might have
explained the failure of anti-cytokine therapy to benefit a heteroge-
neous group of patients with heart failure.”
As his research progresses, Dr. Feldman continues to apply the
knowledge he has gained from mice in the laboratory to humans in
the clinical setting. “I’ve had the opportunity in my career to go back
and forth between the bench and the bedside,” he said. “In our initial
studies in the early 1980s, we were able to use samples of heart
obtained at the time of cardiac transplantation to see if findings in
animal models reflected alterations in the human failing heart. More
recently, we’ve been able to go back and forth between the bench and
the bedside by making comparisons between treatment strategies
aimed at new targets in the mouse models and the effectiveness of
those strategies in humans.”
Currently, Dr. Feldman is focusing his research on trying to
understand the reasons for gender-related differences in survival.
“We’re trying to pursue studies in a myocardial infarction model to
see if we can modulate the post-infarct phenotype,” he explained. “In
addition, we’re trying to learn more about the down-stream effects of
TNF-alpha over-expression by looking at mice that have ablations of
the functions of a variety of proteins that are involved in TNF-
mediated signaling. This allows us to tease apart the various
redundant pathways in the heart.”
In addition, Dr. Feldman and his team are attempting to understand
why patients respond differently to various therapies. “We know that
there are genetic differences in various populations that have caused
mutations to occur in common genes that encode proteins that are
critical for normal heart function or for different responses to injury,”
he said. “These mutations are referred to as polymorphisms. They
have no effect on heart function during normal growth and
development, but when the heart is damaged or stressed, they may
alter the response to that damage in either a good or a bad way. 
Dr. Feldman and his colleagues are studying a large array of different
genes that harbor polymorphisms for their role in either predicting
the development of heart failure or the outcome in patients who have
developed heart failure. Patients are being studied who are enrolled
in one of several ongoing clinical trials in the U.S., and the labora-
tories at Jefferson are serving as the core genetic testing center for
those studies. In addition, Dr. Feldman and his colleagues plan to
acquire genetic samples from a large number of Caucasians, African
Americans, Hispanics, and Asians who have been diagnosed with
heart failure and who receive their care in the Jefferson Health
system. It is hoped that these studies will lead to an identification of
which patients respond best to certain medications and which
patients should receive therapy earlier in their disease.
One day, Dr. Feldman hopes that each patient will have his or her
disease treated with tailored therapy. “I expect that within ten years,
patients will go to their doctors who will prick their finger, take a
small amount of blood, and place it in an automated machine that
will then give them back a genetic profile of that patient,” he said.
“The genetic profile will then be entered into a computer which will
print out a treatment regimen for that patient that will be based on
his genotypic fingerprint. Using this technique, only those patients
that will respond to a drug will receive that drug. Therefore, the cost
of care will be substantially less, but more importantly, patients will
not have to needlessly be exposed to the side effects of medicines that
would not be expected to benefit them. Patients will be able to get a
greater effect with fewer medications.”
Dr. Feldman’s research team consists of six Jeffersonians, as well as a
group of individuals from his laboratory at the University of
Pittsburgh. He also chairs the steering committees of several national
clinical trials assessing the efficacy of new and novel therapies for the
treatment of heart failure. Of his team members, Dr. Feldman stated,
“I’ve been very fortunate over the years to have had a group of
outstanding fellows and wonderful collaborators. It’s those relation-
ships that have really allowed us to answer the questions that we have
been able to approach. I have also been fortunate in being able to
attract several of those collaborators and trainees to Jefferson. My
hope is that because of the richness of this academic environment
and the commitments of the Dean, the University President, and the
Board of Trustees to translational research, we will be able to bring
new investigators to Philadelphia, to develop new relationships with
the outstanding group of scientists already at this institution, and to
continue to push forward the care and treatment of patients with
heart muscle disease.”
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Buchheit Named Chair of Neurosurgery
William A. Buchheit MD has been named Professor and Chairman of
Neurosurgery, succeeding Frederick Simeone MD, who had been
Chairman since 1994.
Dr. Buchheit previously served as
Vice Chairman of the department
from 1995 to 1999. Prior to that
appointment, he was Professor and
Chairman of Neurosurgery of
Temple University School of
Medicine, where he had been a
member of the faculty since 1966.
Dr. Buchheit specialized in treating
brain tumors, particularly acoustic
neuromas.
“We’re very pleased to have Dr. Buchheit with us again at Jefferson,”
says Thomas J. Nasca ’75, Dean of Jefferson Medical College. “His
experience and expertise are uniquely suited to lead our department
of neurosurgery.” Dr. Buchheit has served as President of the
American Academy of Neurological Surgeons and the Society of
University Neurosurgeons, Vice Chairman of the Residency Review
Committee for Neurosurgery as well as governor of the American
College of Surgeons. He is a past member of the American Board of
Neurological Surgery. In 1994, he received the Distinguished Service
Award from the American Association of Neurological Surgeons.
9
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Longtime faculty member Marion J. Siegman PhD, Professor of
Physiology, has been named Chair of the Department. Dr. Siegman,
who had previously been acting Chair, is the first woman chair of a
medical college department at Jefferson. She succeeds Alan Lefer
PhD, Emeritus Professor, who retired in 2001.
Dr. Siegman came to Jefferson in 1967 as an Instructor and by 1977
was the first woman to achieve the rank of full Professor at Jefferson.
She's particularly proud of her portrait commissioned by the medical
college last year because she was chosen by her students and peers to
receive the honor.
Dr. Siegman's research focuses on the biophysics of smooth muscle.
She has authored or
co-authored
numerous peer-
reviewed
publications,
including editing
the monograph
Regulation and
Contraction of
Smooth Muscle. She
says, "It's been
especially exciting
because each step in
the investigational
process leads to
another more
interesting one."
Dr. Siegman earned
her PhD in pharma-
cology in 1966 from the State University of New York, Downstate
Medical Center in Brooklyn, and remained there as a postdoctoral
research associate.
While she continues to pursue her research, she also gets "particular
pleasure from teaching, which has been an unexpected reward from
being at Jefferson." She won the Burlington-Northern Foundation
Award for Excellence in Teaching and Productivity in Research at
Jefferson in 1986. She was awarded the Lindback Award for
excellence in teaching from Jefferson in 1987. She received an
Outstanding Alumna Award from Newcomb College of Tulane
University in 1990. She won the Dean's Award for Teaching
Excellence at Jefferson Medical College in 2000.
In addition to serving on editorial boards, Dr. Siegman has been a
member and reviewer for the Physiology Study Section of the
National Institutes of Health, a member of the Advisory Committee
for Physiology, Cellular and Molecular Biology for the National
Science Foundation, and an ad hoc reviewer for special study sections
for the National Heart, Lung and Blood Institute.
Siegman Chairs Physiology
Vijay M. Rao DR'78, Professor of Radiology and of
Otolaryngology/Head and Neck Surgery, has been named Chair of
Radiology at Jefferson Medical College and Thomas Jefferson
University Hospital. She most
recently served as the department’s
vice chair for education, director of
the radiology residency program,
and co-director of the Division of
Neuroradiology/ENT.
Her research interests include TMJ
imaging, sino-nasal imaging and
dynamic MRI of head and neck
tumors. Philadelphia Magazine for
six years has named Dr. Rao one of
the “Top Docs” in the Philadelphia
area for diagnostic radiology. 
Dr. Rao was recently named President of the Association of Program
Directors in Radiology. The new chair serves as a board examiner for
the American Board of Radiology, and on the editorial executive
committee of Academic Radiology. She chairs the Committee on
Faculty Appointments and Promotions at Jefferson Medical College. 
Dr. Rao is the author of more than 200 papers, presentations and
book chapters. She joined Jefferson 27 years ago in 1975, completing
a diagnostic radiology residency at Thomas Jefferson University
Hospital in 1978.
Rao Appointed Chair of Radiology
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Leonard G. Gomella MD has been named Chair of Urology at
Jefferson Medical College. Dr. Gomella, the Bernard W. Godwin Jr.
Professor of Prostate Cancer and Director of Urologic Oncology at
Jefferson’s Kimmel Cancer Center,
will also serve as chair at Thomas
Jefferson University Hospital.
He is recognized nationally as an
expert in prostate cancer as well as
urologic laparoscopy. In l986, he
began a two-year urologic oncology
fellowship with the Surgery Branch
of the National Cancer Institute in
Bethesda. Dr. Gomella has been on
the faculty of Jefferson Medical
College since 1988.
Dr. Gomella is involved in both basic science and clinical research
in the development of new diagnostic techniques and treatments
for prostate, bladder and kidney cancer.  
Dr. Gomella's team was the first to use PCR to detect microscopic
blood born metastasis in patients with prostate cancer. The
Radiation Therapy Oncology Group (RTOG) has appointed him
urology chairman for the national cooperative group. 
In addition to giving more than 300 presentations at local, national
and international meetings, he has written more than 250 papers,
book chapters and monographs in the field of urology and has
served a member of the editorial board of the Investigative Section
of the Journal of Urology. He has served as co-editor in chief of the
journal Techniques in Urology, on the board of Urologic Oncology
and the Journal of Laparoendoscopic Surgery and as a consultant to
the Journal of Urology, Urology, Cancer Research, the Journal of the
National Cancer Institute, Cancer, Journal of Urologic Oncology, The
Cancer Journal and many others in the field.
Dr. Gomella has authored and edited more than two dozen
different books for medical students, house officers and practicing
physicians, many of which have been translated into foreign
languages. Recovering From Prostate Cancer, written for patients
and their families, was the first book specifically designed for the
general public on this topic. Laparoscopic Urologic Surgery, the first
color operative atlas in this area, is co-edited by Dr. Gomella. In the
field of medicine, Dr. Gomella is widely known for the Clinician's
Pocket Reference, now in its ninth edition.
A P P O I N T M E N T S
Gomella Leads Urology
Richard Wender FP'82, a longtime Jefferson physician who is best
known for his work in cancer prevention and screening, has been
named Chair of the Department of Family Medicine. Dr. Wender
was most recently Vice Chair of the
Department, a position he held since
1995. He is a full Professor. 
Dr. Wender devotes a great deal of time
to the American Cancer Society (ACS),
where he has been president of the
state and local chapters. At the national
level, he is chair of the National Cancer
Control Committee. He is a co-author
of the ACS screening guidelines for
both colon cancer and prostate cancer,
having co-chaired the Prostate Cancer
Screening Guidelines Work Group.
Since 1999, Dr. Wender has been a member of the National Board
of Directors of the ACS.
Dr. Wender is a leader in advocating for improved screening
strategies. He is chairman of the Best Practices in Colorectal Cancer
Awareness and Screening Task Group and co-chair of the Providers
Work Group of the National Colorectal Cancer Roundtable, co-
director of the Colon Cancer Conference of the Cancer Research
Foundation of America and a member of the Oncology
Measurement Advisory Panel of the National Center for Quality
Assurance. Dr. Wender helped to develop the Center for Disease
Control and Prevention's "A Call to Action: Prevention and
Detection of Colorectal Cancer," a widely disseminated web-based
educational program. He has published extensively on cancer,
diabetes and humor in medicine in professional journals including
Cancer, Journal of Family Practice and Archives of Family Medicine.
Dr. Wender is currently co-investigator for a National Institutes of
Health grant titled "Increasing Colon Cancer Screening in Primary
Care" and recently served as a consultant on a U.S. Army Medical
Research and Material Command grant titled "Value Based
Decision Making in Prostate Cancer Early Detection." 
Noted for his warmth and enthusiasm, he is a popular lecturer. He
received the Applied Pharmacology Teaching Award from the
Jefferson Medical College Class of '88. In 1997, he was the Parents
Day Speaker at Jefferson Medical College and in 1999 served as
Class Day Speaker.
After receiving a bachelor of arts degree from Princeton and an MD
from the University of Pennsylvania, Dr. Wender completed a
residency in Family Medicine in 1982 at Thomas Jefferson
University Hospital, where he served as Chief Resident. That year,
he joined the faculty. He directed the family practice residency
from 1985 to 1995.
Wender Heads Family Medicine
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Jefferson Medical College has designated emergency medicine as
an academic department, becoming one of 60 of the nation's 125
medical schools that have upgraded emergency medicine to an
independent department. It was previously a division within
Jefferson's Department of Surgery.
Theodore A. Christopher EM'86, Associate Professor of
Emergency Medicine, has been named the first Chair, having
previously served as
Director of the Division of
Emergency Medicine.
The new designation will
give emergency medicine
an "equality" with other
academic departments in
policy and budgetary
decisions. In addition, all
fourth-year Jefferson
medical students, starting
in 2003, will complete an
educational clerkship in emergency medicine. "Not only does this
raise the status of emergency medicine in the academic setting,"
Dr. Christopher said, "but it will help us in recruiting new
attending physicians and residents."
Emergency medicine is now one of the most popular residencies
among medical students in the United States. There are 12
emergency medicine residency positions available each year in
Jefferson's well-established, three-year training program.
"It's an exciting specialty," said the new chairman, who is
President-elect of the Pennsylvania chapter of the American
College of Emergency Physicians. "It's a unique specialty where
doctors can explore the entire spectrum of medicine."
Among Dr. Christopher's goals for the department are improving
patient satisfaction, making the flow of patient traffic through the
emergency department more efficient and augmenting the depart-
ment's research production. Toward those ends, the department
plans to establish observation and diagnostic units for heart
failure, chest pain and asthma to reduce the waiting time for
patients, and to develop an injury prevention center.
The Emergency Department offers a range of services including
pediatric emergency care, a sexual assault center, an injury
prevention center, travel medicine services and a Workers
Compensation Clinic. The department also oversees the JeffSTAT
transport program and the EMT training center.
New Department of Emergency 
Medicine Will Be Chaired by Christopher
Hospital Is the Best in Philadelphia for
Orthopaedics, Cardiology/Cardiothoracic
Surgery and Rehabilitation Medicine,
According to U.S. News
U.S.News & World Report has once again ranked Thomas Jefferson
University Hospital as  the best hospital in Philadelphia for
orthopaedics, cardiology/cardiothoracic surgery and rehabilitation
medicine.
U.S.News & World Report also determined that Jefferson University
Hospital was among the best in the nation in those medical specialties
and four more areas—cancer, geriatrics, gynecology and urology.
In addition, Wills Eye Hospital, which serves as the Department of
Ophthalmology for Thomas Jefferson University Hospital and
Jefferson Medical College of Thomas Jefferson University, again
ranked as third in the nation and first in Philadelphia for ophthal-
mology.
Jefferson Hospital has major programs for heart disease, cancer
treatment, high-risk childbirth, genetics, radiology, orthopaedics,
digestive diseases and many other areas of medicine and surgery. It is
one of only a few hospitals in the United States that is both a Level I
Trauma Center and a federally designated regional spinal cord injury
center. Jefferson’s Kimmel Cancer Center is designated as a clinical
cancer center by the National Cancer Institute. 
In addition, Jefferson University Hospital and the hospitals of the
Jefferson Cancer Network provide free screenings for breast, skin and
prostate cancers. There are a number of free support programs
available. 
U.S. News assessed care for medical specialties at more than 6,000
hospitals nationwide to determine the rankings. These specialties
were assessed using a three-part model that combines reputation,
mortality and a group of care-related factors such as nursing.
This year’s ranking by the magazine is one among many honors
Jefferson has received over the years. Jefferson physicians have been
named among the best doctors by Philadelphia Magazine and by Best
Doctors in America.
Jefferson University Hospital has also been listed by Solucient
(formerly HCIA-Sachs Institute) as one of the top 100 hospitals in the
United States and the Philadelphia region, as well as one of the top
teaching hospitals in the nation. Solucient also cited Jefferson as
being one of the top 100 hospitals in the nation for:
• Treating heart attacks and cardiovascular disease,
• Providing cost-effective stroke care,
• Having one of the top performing intensive care unit services in the
nation.
In addition, Jefferson University Hospital has been awarded the
Consumer Choice Award for five years in a row by the National
Research Corporation, for being an innovator and leader in health
care in Philadelphia.
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A Follow-Up Visit to the 
University Office of Technology Transfer
Jefferson’s research initiatives have grown remarkably since a
major effort was initiated in 1982 to expand and enlarge this
component of the institution’s mission. The results of good
scientific and medical research enhance the reputation of the
institution and, occasionally, result in increased income to the
institution. The results of good medically oriented research are
scientific achievements that can result in discoveries that
improve the human condition, or can result in technologies and
products with marketable possibilities. The link between
research and industry at Jefferson is the University Office of
Technology Transfer whose role is to obtain patents and
licenses for the new discoveries or inventions of Jefferson’s
faculty or staff, and to assist them in finding industry partners
to develop and market new inventions and discoveries of
Jefferson researchers. (see "Technology Transfer: Jefferson's
Link Between Research and Industry," JMC Alumni Bulletin,
December 1996).
The technology transfer program at Jefferson was created in
1984 to capture opportunities in basic and clinical research and
to develop them into marketable products in a timely fashion.
Patenting and licensing of specific discoveries and inventions
usually are necessary steps in converting basic science discov-
eries into useful products that can be made widely available for
health care use. Efforts of the Office of Technology Transfer add
a new and motivating dimension to research activity. Taking a
discovery or product from a basic idea to a clinical use, or to an
actual product that can benefit the whole population, is a task
that can be accomplished best by combining the research and
clinical capabilities of an institution like Jefferson with the
product development, manufacturing, and marketing capabil-
ities of industry.
Jefferson’s technology transfer program seeks to facilitate this
development by securing patent protection to give industry the
incentive to invest significant resources into development of the
product or invention, in coordination with the department
sponsoring the research. This activity is followed by licensing
the technology or product to an existing company, or to a new
start up company specifically formed to develop and market the
new Jefferson technology or invention. The University Counsel
provides legal analyses in licensing issues and reviews license
agreements. In addition, the Technology Transfer Website
provides information to both the Jefferson community and to
industry. The University recognizes that, in certain instances,
the public interest may be served best through the licensing of
an invention or product to a newly created or an early stage
company. Such a company may make a more focused effort to
commercially develop a product or invention to make it
available to the public. In order to maximize company funds
available for development of the product or invention, the
company may offer, and the University may accept, equity in the
company in lieu of cash license fees as full or partial consider-
ation for the license. At the end of 2000, total license-related
research funding at Jefferson since 1984 was over $38 million,
and license revenues totaled about $7.5 million.
Jefferson’s research base has increased dramatically in the last 15
years, rising from $10 million in 1987 to approximately $100
million today. Some 70 percent of this funding is in grant
support from the National Institutes of Health. The Office of
Technology Transfer has received more than 1,000 invention
disclosures from the faculty with more than 200 U.S. patents
obtained. Nearly $50 million has come to the University in
licensing fees, research funding and equity to date from products
and inventions developed by Jefferson faculty members. As an
example of how this activity can come about, suppose a Jefferson
researcher interested in ulcerative colitis identifies a specific
target molecule present only in some tissue cells in the part of
the colon affected by ulcerative colitis. Suppose he or she next
develops an antibody to block the protein and disable it so it no
longer can stimulate the immune system and cause inflammation
in the colon. With permission from the Institutional Review
Board (IRB), the newly developed molecular antibody can be
tested in clinical trials. If these clinical trials show successful
patient results with this newly developed molecular antibody,
the Office of Technology Transfer can prepare a U.S. patent
application, followed by negotiations with industry to identify an
appropriate biotechnology company, or a new start up company,
who then can be licensed to develop this molecular antibody for
wider clinical use.
Not all discoveries or inventions made at Jefferson are judgedof sufficient importance to warrant patenting. Each
Jefferson researcher requesting patent protection is given a full
and fair hearing, but the final decision will rest on the potential
commercial value of each invention or discovery. The cost for
the patent application is assumed by the University. Although
the patent is issued to the investigator, the intellectual property
is owned by the University, and all derived revenue is shared
between the investigator and the institution in certain
percentages as specified in the Thomas Jefferson University
Patent Policy. The institution’s share of the proceeds is justified
by the fact the institution provides the space, laboratory,
equipment and consulting staff that made the discovery possible.
All equity acquired by Jefferson from these patents and start up
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companies is managed by the University Treasurer who uses
reasonable business judgment on when to sell any or all
Jefferson equity so acquired. In addition, any agreement signed
with industry may not impede the fabric of free inquiry, open
discussion, the sharing of materials, or the right of prompt
publication of results. Jefferson believes the best research and
teaching are done in an environment that minimizes extrinsic
inducements, nurtures free inquiry and broad dissemination of
information, and one that has clear, specific, and credible
policies on conflicts of interest.
In December 2002, the Director of the University Office of
Technology Transfer, Abram Goldfinger, was recruited to a large
private university to head their technology transfer program,
and Mr. Richard Miller, the Assistant Director, was asked to
serve as the Acting Director for the period needed to recruit a
new Director. Over the ensuing year, a nationwide search was
conducted with the assistance of a search firm. From seven good
candidates, the Search Committee selected Ms. Katherine Chou
who comes to Jefferson with a degree in chemistry, an MBA
degree, an extensive background in business and six years of
experience as a technology transfer officer in the Office of
Technology Licensing at Harvard University. Ms. Chou began
her new duties as Director of the Office of Technology Transfer
at Jefferson on September 1, 2002. Ms. Chou, a charming and
energetic person, reports to Dr. Jussi Saukkonen, Dean and Vice
President for Science Policy, Technology Development and
International Affairs, and to the Biotechnology Committee of the
Board of Trustees. Her office is responsible for managing the
protection of intellectual property at Jefferson, including
patents. She develops business plans and helps to create start up
companies. She also negotiates and reviews license, research and
clinical trial agreements between Jefferson and corporations.
Ms. Chou believes she has instituted better marketing efforts in
the office since taking charge of the University Office of
Technology Transfer. She recognizes that Jefferson has limited
resources so she believes it is necessary for her office to obtain as
high a value as possible for any new product, drug, or invention
developed at Jefferson. She also believes her office must be
driven by the possible commercial value to Jefferson inherent in
any new product, drug, or invention. She points out that as soon
as a patent application is in place she initiates marketing efforts.
She believes it is too late for effective marketing if the office
waits to begin these efforts until after a patent is granted. Before
initiating any marketing efforts, she meets with the researcher or
inventor who gives her key words about the research finding or
invention to use in the marketing effort. She uses these key
words when searching the Internet for possible commercial
partners. She then sends a non confidential summary to 25 to 30
potential company partners to test their interest in the research
finding or invention. She also makes it a policy to keep
researchers and inventors informed by sharing company
feedback with them about the results of these initial marketing
efforts.
Ms. Chou also has initiated what she calls a “taking your ideas to
reality” program because, as she points out, Jefferson’s research
faculty members are her office's clients. She regards the efforts of
her office simply as the service that helps them develop their
research findings commercially so the findings can have a wider
public application. She meets with all the formal research
committees on campus, as well as with departmental researchers
and research administrators on a regular basis, to keep them
aware of the possible benefits that can accrue to them and to the
University from the efforts of the Office of Technology Transfer
on their behalf.  She points out that Jefferson now has over 700
research faculty members and she makes a special effort to make
certain that all of them know about the services that can be
provided to and for them by the University Office of Technology
Transfer.
After starting at Jefferson, Ms. Chou became concerned aboutthe legal expenses the University had been paying for patent
filings and the expenses involved with licensing particular
technologies or inventions to certain companies. Once a
company has licensed a particular technology or invention the
company then becomes responsible for all legal expenses. Ms.
Chou, arguing that the University is a legitimate nonprofit
organization, has been able to convince the involved companies
that have licensed Jefferson technologies or inventions to
reimburse Jefferson for these initial legal expenses. To date, she
has recovered over $300,000 for Jefferson in paid out legal
expenses from the involved companies.
At the end of 2002, Jefferson held $12 million in equity in about
40 companies. Ms. Chou anticipates a Technology Transfer
income of approximately $1.5 million in 2003. Judging from the
perspective of 20 years, Jefferson’s decision to add a research
component to the University and to develop an Office of
Technology Transfer to capitalize on Jefferson’s research
findings and inventions certainly has proven to be a wise
decision from a financial standpoint. It also is a decision that is
in keeping with the academic mission of Jefferson Medical
College and the University as a whole, particularly in these
uncertain times of rising expenses and limited resources.
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